Prometheus reportedly drew a competing AbbVie bid, initial partner interest from 16 pharmas before inking $10.8B Merck buyout
In the week after this year’s JP Morgan Healthcare Conference, Prometheus Biosciences CEO Mark McKenna got a phone call that would change the biotech’s future.
Sunil Patel, Merck’s head of business development and licensing, rang up McKenna on Jan. 19, just a week after McKenna had chatted with execs from Merck, along with five other mid- to large-cap pharma companies at JPM in San Francisco.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,400+ biopharma pros reading Endpoints daily — and it's free.